Key Highlights
- Third quarter loss per share was USD 0.46 against an estimated USD 0.56 loss, with no Revenue reported.
- Cash was USD 24.6 million, up from USD 13.2 million, with runway guided into the second quarter of 2027.
- The company plans an NDA submission seeking Accelerated Approval in the first half of 2027 for iopofosine I-131.
- Management guided that the confirmatory Phase 3 study is to dose its first patient in the first quarter of 2027.
Cellectar Biosciences (NASDAQ:CLRB), a clinical-stage company developing the radiopharmaceutical iopofosine I-131 for relapsed or refractory Waldenstrom macroglobulinemia, reported a third quarter 2026 loss of USD 0.46 per share, narrower than the USD 0.56 estimated loss. The company reported no revenue. Net loss for the nine months was approximately USD 20.6 million, and operations used about USD 20.3 million in cash.
Research and development expenses were approximately USD 5.4 million for the quarter, compared with USD 2.5 million a year earlier, and USD 13.0 million for the nine months, against USD 8.3 million. General and administrative expense was about USD 2.7 million, up from USD 2.3 million, and USD 8.1 million for the nine months, down from USD 8.9 million. Combined research and administrative spending for the quarter was about USD 8.1 million, against about USD 4.9 million a year earlier, so spending is rising as the Phase 3 program is set up. The nine-month figure reflects higher research outlays partly offset by lower administrative costs.
Cash and Financing
Cash and cash equivalents were approximately USD 24.6 million at quarter end, compared with USD 13.2 million at December 31, 2025. In early May the company completed a financing of up to USD 140 million, made up of an upfront payment of USD 35 million and USD 105 million of milestone-based capital. Management guided that cash runway extends into the second quarter of 2027, which it said is sufficient to reach planned catalysts, including starting the confirmatory trial.
Clinical and Regulatory Path
The filing describes the CLOVER-WaM Phase 2b pivotal trial, which reported statistically significant outcomes on both the primary endpoint of major response rate and the secondary endpoint of median duration of response. The FDA has granted Breakthrough Therapy Designation to the therapy.
In October the company presented additional CLOVER-WaM analysis at an international workshop, showing a major response rate of 79.2% and a median duration of response of 16 months in patients treated immediately after BTK inhibitor therapy. Updated 12-month follow-up data were also presented.
The company has recently initiated its confirmatory Phase 3 study and is advancing a Phase 1b dosimetry study that includes an option to enroll first and second-line patients. Site activation and study startup for the Phase 3 trial are progressing, and management guided that the first patient is to be dosed in the first quarter of 2027. A New Drug Application seeking accelerated approval is planned for submission in the first half of 2027.
Factors to Follow
The items to follow are whether the milestone-based portion of the financing is released as conditions are met, the pace of Phase 3 site activation, the dosimetry study progress and the timing of the application. With runway guided into the second quarter of 2027, further financing is a recurring consideration for readers.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...